# Alexander Paliege

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alexander-paliege/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,031 |
| Field | Ion Transport and Channel Regulation |
| h-index | 30 |
| i10-index | 50 |
| Last Known Institution | University Hospital Carl Gustav Carus |
| OpenAlex ID | https://openalex.org/A5055798055 |
| ORCID iD | 0000-0001-5092-5472 |
| Works | 106 |

## Researcher papers

- [Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors](https://scholariq.org/papers/mediation-of-tubuloglomerular-feedback-by-adenosine-evidence-from-mice-lacking/)
- [The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension](https://scholariq.org/papers/the-calcineurin-inhibitor-tacrolimus-activates-the-renal-sodium-chloride/)
- [Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine](https://scholariq.org/papers/humoral-and-cellular-immunity-to-sars-cov-2-vaccination-in-renal-transplant/)
- [Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-a-targeted-release-formulation-of-budesonide-in-patients/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial](https://scholariq.org/papers/efficacy-and-safety-of-aldosterone-synthase-inhibition-with-and-without/)
- [Hypoxia-inducible factor-2α-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization](https://scholariq.org/papers/hypoxia-inducible-factor-2-expressing-interstitial-fibroblasts-are-the-only/)
- [The pathological features of regulated necrosis](https://scholariq.org/papers/the-pathological-features-of-regulated-necrosis/)
- [Vasopressin V<sub>2</sub>receptor expression along rat, mouse, and human renal epithelia with focus on TAL](https://scholariq.org/papers/vasopressin-v-sub-2-sub-receptor-expression-along-rat-mouse-and-human-renal/)
- [Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse)](https://scholariq.org/papers/key-enzymes-for-renal-prostaglandin-synthesis-site-specific-expression-in-rodent/)
- [Con: Tolvaptan for autosomal dominant polycystic kidney disease—do we know all the answers?](https://scholariq.org/papers/con-tolvaptan-for-autosomal-dominant-polycystic-kidney-disease-do-we-know-all/)

## Researcher topics

- [Ion Transport and Channel Regulation](https://scholariq.org/topics/ion-transport-and-channel-regulation/)
- [Electrolyte and hormonal disorders](https://scholariq.org/topics/electrolyte-and-hormonal-disorders/)
- [Nitric Oxide and Endothelin Effects](https://scholariq.org/topics/nitric-oxide-and-endothelin-effects/)
- [S100 Proteins and Annexins](https://scholariq.org/topics/s100-proteins-and-annexins/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Researcher university

- [University Hospital Carl Gustav Carus](https://scholariq.org/institutions/university-hospital-carl-gustav-carus/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.